indacaterol
Selected indexed studies
- Indacaterol. (, 2006) [PMID:30000976]
- Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. (N Engl J Med, 2016) [PMID:27181606]
- Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma. (Drugs, 2021) [PMID:33871819]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma. (2022) pubmed
- Indacaterol. (2006) pubmed
- Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. (2016) pubmed
- Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma. (2021) pubmed
- Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. (2018) pubmed
- Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. (2020) pubmed
- Indacaterol for chronic obstructive pulmonary disease. (1994) pubmed
- Indacaterol: a comprehensive review. (2013) pubmed
- The safety of indacaterol for the treatment of COPD. (2018) pubmed
- Indacaterol. (2011) pubmed